Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome

Andrew Butler, Yihong Zhang, Alan G Stuart, Christopher E Dempsey, Jules C Hancox

Research output: Contribution to journalArticle (Academic Journal)peer-review

8 Citations (Scopus)
291 Downloads (Pure)


The hERG potassium channel is critical to normal repolarization of cardiac action potentials (APs) and loss‐ and gain‐of‐function hERG mutations are associated, respectively, with long and short QT syndromes, pathological conditions that can lead to arrhythmias and sudden death. hERG current (IhERG) exhibits uniquely fast inactivation involving conformational changes to the channel pore. The S631A hERG pore mutation was originally engineered to interrogate hERG channel inactivation, but has very recently been found in a family with short QT syndrome (SQTS). Accordingly, this study characterized the effects of the S631A mutation on IhERG profile during ventricular, atrial, and Purkinje fiber (PF) AP waveforms, using patch clamp recording from hERG expressing HEK 293 cells at 37°C. Under conventional voltage clamp, the current–voltage (IV) relation for IhERG exhibited a marked right‐ward shift in the region of negative slope at positive membrane potentials. Under ventricular AP clamp, the S631A mutation resulted in augmented IhERG, which also peaked much earlier during the AP plateau than did wild‐type (WT) IhERG. Instantaneous IV relations showed a marked positive shift in peak repolarizing current during the ventricular AP in the S631A setting, while the instantaneous conductance‐voltage relation showed an earlier and more sustained rise in S631A compared to WT IhERG conductance during ventricular repolarization. Experiments with atrial and PF APs in each case also showed augmented and positively shifted IhERG in the S631A setting, indicating that the S631A mutation is likely to accelerate repolarization in all three cardiac regions. Ventricular AP clamp experiments showed retained effectiveness of the class Ia antiarrhythmic drug quinidine (1 μmol/L) against S631A IhERG. Quinidine is thus likely to be effective in reducing excessively fast repolarization in SQTS resulting from the S631A hERG mutation.
Original languageEnglish
Article numbere13845
Number of pages14
JournalPhysiological Reports
Issue number17
Early online date2 Sept 2018
Publication statusPublished - Sept 2018


  • Arrhythmia
  • atrial fibrillation
  • hERG
  • KCNH2
  • quinidine
  • S631A
  • short QT syndrome


Dive into the research topics of 'Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome'. Together they form a unique fingerprint.

Cite this